{"nctId":"NCT03761810","briefTitle":"A Study of S6G5T3 in the Treatment of Acne Vulgaris","startDateStruct":{"date":"2018-12-14","type":"ACTUAL"},"conditions":["Acne Vulgaris"],"count":434,"armGroups":[{"label":"S6G5T-3","type":"EXPERIMENTAL","interventionNames":["Drug: S6G5T-3"]},{"label":"S6G5T-8 Vehicle Cream","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: S6G5T-8"]}],"interventions":[{"name":"S6G5T-3","otherNames":["Encapsulated Benzoyl Peroxide (E-BPO) and Encapsulated Tretinoin (E-ATRA) Cream, (E-BPO/E-ATRA Cream)"]},{"name":"S6G5T-8","otherNames":["Vehicle"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Participant must sign an Institutional Review Board (IRB) approved written informed consent for this study.\n2. Male and female 9 years of age and older.\n3. Have 2 or fewer cysts or nodules.\n\nExclusion Criteria:\n\n1. More than 2 acne nodules or cysts (defined as an inflammatory lesion greater than or equal to 5 millimeter \\[mm\\] in diameter).\n2. Acne conglobata, acne fulminans and secondary acne (for example, chloracne, drug-induced acne).\n3. History of blood dyscrasia (for example, leukemia, haemophilia, sickle cell anemia, multiple myeloma).\n4. Underlying disease that requires the use of interfering topical or systemic therapy.\n5. Other dermatological conditions that require the use of interfering topical or systemic therapy or that might interfere with study assessments such as, but not limited to, atopic dermatitis, perioral dermatitis, or rosacea.","healthyVolunteers":false,"sex":"ALL","minimumAge":"9 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants Achieving an IGA Score of Clear or Almost Clear and a Score â‰¥2 Grades Less Than Baseline","description":"Percentage of participants in each treatment group achieving an acne severity IGA score of \"clear (score=0)\" or \"almost clear (score=1)\" and achieving an acne severity IGA score of at least 2 grades less than Baseline.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25.4","spread":null},{"groupId":"OG001","value":"14.7","spread":null}]}]}]},{"type":"PRIMARY","title":"Change From Baseline in Inflammatory Lesion Counts on the Face at Week 12","description":"Inflammatory lesions were characterized by papules, pustules, nodules, and cysts. Least squares means and standard deviations from an analysis of covariance (ANCOVA) with factors of treatment group and analysis center and the respective Baseline lesion count as a covariate. Negative least squares means values represent decrease from Baseline.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-16.2","spread":"9.07"},{"groupId":"OG001","value":"-14.1","spread":"8.68"}]}]}]},{"type":"PRIMARY","title":"Change From Baseline in Non-Inflammatory Lesion Counts on the Face at Week 12","description":"Non-inflammatory lesions were characterized by open comedones (blackheads) and closed comedones (whiteheads). Least squares means and standard deviations from an ANCOVA with factors of treatment group and analysis center and the respective Baseline lesion count as a covariate. Negative least squares means values represent decrease from Baseline.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-24.2","spread":"15.82"},{"groupId":"OG001","value":"-17.4","spread":"15.82"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Non-Inflammatory Lesion Counts on the Face at Week 12","description":"Non-inflammatory lesions were characterized by open comedones (blackheads) and closed comedones (whiteheads). Least squares means and standard deviations from an ANCOVA with factors of treatment group and analysis center and the respective Baseline lesion count as a covariate. Negative least squares means values represent decrease from Baseline.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-54.4","spread":"32.28"},{"groupId":"OG001","value":"-41.5","spread":"33.44"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Inflammatory Lesion Counts on the Face at Week 12","description":"Inflammatory lesions were characterized by papules, pustules, nodules, and cysts. Least squares means and standard deviations from an ANCOVA with factors of treatment group and analysis center and the respective Baseline lesion count as a covariate. Negative least squares means values represent decrease from Baseline.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-57.6","spread":"32.41"},{"groupId":"OG001","value":"-50.8","spread":"31.17"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving at Least a 4-Point Reduction on Item 1 (Pimple) of the Patient-Reported Evaluation of Facial Acne (Pre-Face)","description":"Percent of participants in each treatment group achieving at least a 4 point reduction on Item 1 (Pimple) of the patient- reported evaluation of facial acne compared to Baseline. The Pre-Face is a 7-item questionnaire that assesses acne vulgaris-related signs, symptoms, and impacts. Item 1 of the questionnaire was to assess the pimples on the participant's face at their worst in the 24 hours prior to administration on an 11-point numeric rating scale (NRS) ranging from 0 (\"no pimples at all\") to 10 (\"pimples as bad as you can imagine\").","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"35.1","spread":null},{"groupId":"OG001","value":"27.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving at Least a 4-Point Reduction on Item 5 (Embarrassment) of the Pre-Face","description":"Percent of participants in each treatment group achieving at least a 4 point reduction on Item 5 (Embarrassment) of the patient reported evaluation of facial acne compared to Baseline. The Pre-Face is a 7-item questionnaire that assesses acne vulgaris-related signs, symptoms, and impacts. Item 5 of the questionnaire was to assess how embarrassed the participant felt because of the acne at their worst, in the 24 hours prior to administration on an 11-point NRS ranging from 0 (\"not embarrassed at all\") to 10 (\"extremely embarrassed\").","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"33.9","spread":null},{"groupId":"OG001","value":"37.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Non-Inflammatory Lesion Counts on the Face at Week 8","description":"Non-inflammatory lesions were characterized by open comedones (blackheads) and closed comedones (whiteheads). Least squares means and standard deviations from an ANCOVA with factors of treatment group and analysis center and the respective Baseline lesion count as a covariate. Negative least squares means values represent decrease from Baseline.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-20.0","spread":"16.43"},{"groupId":"OG001","value":"-12.8","spread":"16.21"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Inflammatory Lesion Counts on the Face at Week 8","description":"Inflammatory lesions were characterized by papules, pustules, nodules, and cysts. Least squares means and standard deviations from an ANCOVA with factors of treatment group and analysis center and the respective Baseline lesion count as a covariate. Negative least squares means values represent decrease from Baseline.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-14.0","spread":"8.57"},{"groupId":"OG001","value":"-12.5","spread":"8.57"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Non-Inflammatory Lesion Counts on the Face at Week 4","description":"Non-inflammatory lesions were characterized by open comedones (blackheads) and closed comedones (whiteheads). Least squares means and standard deviations from an ANCOVA with factors of treatment group and analysis center and the respective Baseline lesion count as a covariate. Negative least squares means values represent decrease from Baseline.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-14.6","spread":"14.51"},{"groupId":"OG001","value":"-10.8","spread":"14.88"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Inflammatory Lesion Counts on the Face at Week 4","description":"Inflammatory lesions were characterized by papules, pustules, nodules, and cysts. Least squares means and standard deviations from an ANCOVA with factors of treatment group and analysis center and the respective Baseline lesion count as a covariate. Negative least squares means values represent decrease from Baseline.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.7","spread":"7.94"},{"groupId":"OG001","value":"-10.1","spread":"7.81"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":281},"commonTop":["Application site pain","Application site dryness","Application site exfoliation","Application site erythema","Application site dermatitis"]}}}